Valetudo Therapeutics LLC
Known title: 10% OwnerCIK: 0002067359
Associated companies
Transaction History
| LIMN | ▼ Sell | Other | 3,448,926 | — | 7/2/2026 | View on chart |
| LIMN | ▼ Sell | Other | 4,373,603 | — | 6/24/2026 | View on chart |
| LIMN | ▼ Sell | Other | 3,448,926 | — | 7/2/2026 | View on chart |
| LIMN | ▼ Sell | Other | 4,373,603 | — | 6/24/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Liminatus Pharma Regains Nasdaq Compliance
Liminatus Pharma announced it has regained compliance with Nasdaq's minimum bid price rule. This development addresses a regulatory requirement that, if not met, can lead to delisting. The stock remains well below its 52-week high, reflecting the broader challenges the company has faced recently.
Liminatus Pharma Regains Nasdaq Compliance. Liminatus Pharma announced it has regained compliance with Nasdaq's minimum bid price rule. This development addresses a regulatory requirement that, if not met, can lead to delisting. The stock remains well below its 52-week high, reflecting the broader challenges the company has faced recently.